NewsBenzingaMorgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $57 Morgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $57 Benzinga 2026.09.23 11:36 (GMT+0) Open on Benzinga Other news IonQ Quantum Computer to Power Nvidia's Quantum Lab Travala Launches Permanent AVA Strategic Reserve, Doubles Monthly Open-Market Buybacks Galaxy adds $100 million in sUSDS to corporate treasury and approves it as collateral for institutional trading Ema raises $77M as AI starts eating into enterprise software and services Apple Stock Nears Record High. Why $400 Could Be Next. Is NRG Energy Stock Underperforming the S&P 500?
Galaxy adds $100 million in sUSDS to corporate treasury and approves it as collateral for institutional trading
